Hofheinz RD, Hegewisch-Becker S, Kunzmann V, et al. - Among patients with locally advanced esophagogastric adenocarcinomas (EGA) who were enrolled in a multicenter phase II study, researchers tested the combination of trastuzumab and FLOT (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) as perioperative treatment, focusing on its efficacy and toxicity. Patients with human epidermal growth factor receptor 2 positive EGA were administered perioperative FLOT. Patients had ≥ cT2, any N, M0 EGA. There were 56 evaluable patients (median age 62 years). Leukopenia (17.9%), neutropenia (46.6%) and diarrhea (17.0%) were documented as main adverse events grades 3-4. Tumor resections were performed in all patients. A R0 resection rate of 92.9% was noted. Anastomotic leakage occurred in eight patients. Twelve patients (21.4%) achieved pCR (pathological complete response), and near complete response was evident in a further n = 14 patients (25.0%). A median disease-free survival of 42.5 months and 3-year overall survival rate of 82.1% was obtained. A pCR >20% was achieved (primary endpoint). No unexpected safety issues emerged and promising survival data were offered.